TREATMENT CELLS CELL

Brand Owner (click to sort) Address Description
ADAPT CRUCELL HOLLAND B.V. Archimedesweg 4 2333CN Leiden Netherlands Treatment of cells and cell lines, viruses, polynucleic acids, polynucleotides, proteins, polypeptides and biochemicals for use in the manufacture of pharmaceuticals of genetic biochemicals;Genetic modified cells and cell lines, viruses, polynucleic acids, polynucleotides, proteins, polypeptides and biochemicals all for medical and clinical use;Genetic modified cells and cell lines, viruses, polynucleic acids, polynucleotides, proteins, polypeptides and biochemicals all for use in the manufacture of pharmaceuticals and for scientific and laboratory research;Scientific research; services in the medical and biochemical field, especially the examination and testing of genes, development, examination and testing of pharmaceutical and biochemical semi-finished products especially for use in medicines, the development, examination and testing of medicines, the development of test systems for genetically modified material for the preparation of pharmaceutical products and for research and diagnostic purposes;
ADRANDOM GALAPAGOS GENOMICS N.V. Generaal de Wittelaan, L11 B4 2800 Mechelen Belgium Treatment of cells and cell lines, viruses, polynucleic acids, polynucleotides, proteins, polypeptides and biochemicals for use in the manufacture of pharmaceuticals or genetic modified biochemicals;Genetic modified cell and cell lines, viruses, polynucleic acids, polynucleotides, proteins, polypeptides and biochemicals all for medical and clinical use;Genetic modified cell and cell lines, viruses, polynucleic acids, polynucleotides, proteins, polypeptides and biochemicals all for use in the manufacture of pharmaceuticals and for scientific and laboratory research;Scientific research; services in the medical and biochemical field, especially the examination and testing of genes, development, examination and testing of pharmaceutical and biochemical semi-finished products especially for use in medicines, the development, examination and testing of medicines, the development of test systems for genetically modified material for the preparation of pharmaceutical products and for research and diagnostic purposes;
 

Where the owner name is not linked, that owner no longer owns the brand

    
Technical Examples
  1. A treatment solution used to prevent posterior capsular opacification is applied or introduced into the lens capsular bag before, during, or after cataract surgery. The treatment solution comprises an ion transport mechanism interference agent, which either alone or in combination with other treatment agents such as an osmotic stress agent and an agent to establish a suitable pH, selectively induces detachment and/or death of lens epithelial cells such that posterior capsular opacification is prevented. While the ion transport mechanism interference agent is capable of interfering with the cellular mechanisms and cell ion distribution of a broad range of cells, a concentration of agent is selected such that the treatment solution interferes selectively with the cellular mechanisms of lens epithelial cells while leaving other ocular cells substantially unharmed. The treatment solution selectively induces cellular death and/or detachment of lens epithelial cells while other ocular cells and tissue remain substantially unharmed and without lengthy preoperative pre-treatment.